Viatris is a healthcare company. Co.'s portfolio comprises of approved molecules across a range of therapeutic areas, including brands, generic, complex generic and biosimilars. From cardiovascular health to oncology, Co. provides treatment options across therapeutic areas covering a variety of non-communicable and infectious diseases. Co. also provides support services such as diagnostic clinics, educational seminars and digital tools. Co. provides a range of treatment options across all its therapeutic areas, with several categories containing several products in a range of dosage forms, formulations and delivery systems that allow physicians to tailor care for optimal treatment.
When researching a stock like Viatris, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from VTRS Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for VTRS stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the VTRS 200 day moving average ("VTRS 200 DMA"), while one of the most popular "shorter look-backs" is the VTRS 50 day moving average ("VTRS 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Viatris. |
Free VTRS Email Alerts:
Video: Technical Analysis